Sulfated Polysaccharide, Curdlan Sulfate, Efficiently Prevents Entry/Fusion and Restricts Antibody-Dependent Enhancement of Dengue Virus Infection In Vitro: A Possible Candidate for Clinical Application

PLoS Neglected Tropical Diseases

Volumn 7, Issue 4, 2013, Pages

  Ichiyama, Koji ^a,b   Gopala Reddy, Sindhoora Bhargavi ^a,c   Zhang, Li Feng ^a   Chin, Wei Xin ^a   Muschin, Tegshi ^d   Heinig, Lars ^a   Suzuki, Youichi ^a   Nanjundappa, Haraprasad ^c   Yoshinaka, Yoshiyuki ^e   Ryo, Akihide ^b   Nomura, Nobuo ^f   Ooi, Eng Eong ^g   Vasudevan, Subhash G ^g   Yoshida, Takashi ^d   Yamamoto, Naoki ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c SRI JAYACHAMARAJENDRA COLLEGE OF ENGINEERING   (India)

^d KITAMI INSTITUTE OF TECHNOLOGY   (Japan)

^e TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^f MUSASHINO UNIVERSITY   (Japan)

^g DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CURDLAN; LUCIFERASE; POLYSACCHARIDE SULFATE;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL FUSION; CHEMICAL ANALYSIS; CYTOTOXICITY; DENGUE; ELECTRON MICROSCOPY; FLUORESCENCE ACTIVATED CELL SORTING; HYDROGEN BOND; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; NONHUMAN; PLAQUE FORMING CELL; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; ULTRAFILTRATION; VIRUS ATTACHMENT;

EID: 84876821169     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002188     Document Type: Article

References (68)

1. Gubler DJ, (2004) Cities spawn epidemic dengue viruses. Nature Medicine 10: 129-130.
2. Racloz V, Ramsey R, Tong S, Hu W, (2012) Surveillance of Dengue Fever Virus: A Review of Epidemiological Models and Early Warning Systems. PLoS Negl Trop Dis 6: e1648.
3. WHO (2002) Dengue and Dengue Haemorrhagic Fever. Fact Sheet No. 117. Geneva: World Health Organisation.
4. Rigau-Perez J, Clark G, Gubler D, Reiter P, Sanders E, et al. (1998) Dengue and Dengue haemorrhagic fever. The Lancet 352: 971-977.
5. Heinz FX, Stiasny K, (2012) Flaviviruses and flavivirus vaccines. Vaccine 30: 4301-4306.
6. Noble CG, Chen YL, Dong H, Gu F, Lim SP, et al. (2010) Strategies for development of Dengue virus inhibitors. Antiviral Res 85: 450-462.
7. Parkinson T, Pryde DC, (2010) Small molecule drug discovery for Dengue and West Nile viruses: applying experience from hepatitis C virus. Future Med Chem 2: 1181-1203.
8. Hsieh SC, Tsai WY, Wang WK, (2010) The length of and nonhydrophobic residues in the transmembrane domain of dengue virus envelope protein are critical for its retention and assembly in the endoplasmic reticulum. J Virol 84: 4782-4797.
9. Kapoor M, Zhang L, Ramachandra M, Kusukawa J, Ebner KE, et al. (1995) Association between NS3 and NS5 proteins of dengue virus type 2 in the putative RNA replicase is linked to differential phosphorylation of NS5. J Biol Chem 270: 19100-19106.
10. Keller TH, Chen YL, Knox JE, Lim SP, Ma NL, et al. Finding new medicines for flaviviral targets. Novartis Found Symp 277: 102-114.
11. Mondotte JA, Lozach P, Amara A, Gamarnik AV, (2007) Essential Role of Dengue Virus Envelope Protein N Glycosylation at Asparagine-67 during Viral Propagation. J Virol 81: 7136-7148.
12. Rey FA, (2003) Dengue virus envelope glycoprotein structure: new insight into itsinteractions during viral entry. Proc Natl Acad Sci USA 100: 6899-6901.
13. Modis Y, Ogata S, Clements D, Harrison SC, (2003) A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A 100: 6986-6991.
14. Yang JM, Chen YF, Tu YY, Yen KR, Yang YL, (2007) Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors. PLoS One 2: e428.
15. Zhou Z, Khaliq M, Suk JE, Patkar C, Li L, et al. (2008) Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein. ACS Chem Biol 3: 765-775.
16. Li Z, Khaliq M, Zhou Z, Post CB, Kuhn RJ, et al. (2008) Design, synthesis, and biological evaluation of antiviral agents targeting flavivirus envelope proteins. J Med Chem 51: 4660-4671.
17. Kampmann T, Yennamalli R, Campbell P, Stoermer MJ, Fairlie DP, et al. (2009) In silico screening of small molecule libraries using the dengue virus envelope E protein has identified compounds with antiviral activity against multiple flaviviruses. Antiviral Res 84: 234-241.
18. Wang QY, Patel SJ, Vangrevelinghe E, Xu HY, Rao R, et al. (2009) A small-molecule dengue virus entry inhibitor. Antimicrob Agents Chemother 53: 1823-1831.
19. Poh MK, Yip A, Zhang S, Priestle JP, Ma NL, et al. (2009) A small molecule fusion inhibitor of dengue virus. Antiviral Res 84: 260-266.
20. Yennamalli R, Subbarao N, Kampmann T, McGeary RP, Young PR, et al. (2009) Identification of novel target sites and an inhibitor of the dengue virus E protein. J Comput Aided Mol Des 23: 333-341.
21. Modis Y, Ogata S, Clements D, Harrison SC, (2004) Structure of the dengue virus envelope protein after membrane fusion. Nature 427: 313-319.
22. Nakashima H, Yoshida O, Tochikura TS, Yoshida T, Mimura T, et al. (1987) Sulfation of polysaccharides generates potent and selective inhibitors of human immunodeficiency virus infection and replication in vitro. Jpn J Cancer Res 78: 1164-1168.
23. Kaneko Y, Yoshida O, Nakagawa R, Yoshida T, Date M, et al. (1990) Inhibition of HIV-1 infectivity with curdlan sulfate in vitro. Biochem Pharmacol 39: 793-797.
24. Yoshida T, Yasuda Y, Mimura T, Kaneko Y, Nakashima H, et al. (1995) Synthesis of curdlan sulfates having inhibitory effects in vitro against AIDS viruses HIV-1 and HIV-2. Carbohydr Res 276: 425-436.
25. Evans SG, Morrison D, Kaneko Y, Havlik I, (1998) The effect of curdlan sulphate on development in vitro of Plasmodium falciparum. Trans R Soc Trop Med Hyg 92: 87-89.
26. Havlik I, Looareesuwan S, Vannaphan S, Wilairatana P, Krudsood S, et al. (2005) Curdlan sulphate in human severe/cerebral Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 99: 333-340.
27. Thomsen R, Christensen MH, (2006) MolDock: A New Technique for High-Accuracy Molecular Docking. J Med Chem 49: 3315-3321.
28. Schrodinger LLC (2012) Schrodinger Suite 2012 Induced Fit Docking protocol; Glide version 5.8. New York, NY: Schrodinger, LLC.
29. Sherman W, Day T, Jacobson MP, Friesner RYA, Farid R, (2006) Novel Procedure for Modeling Ligand/Receptor Induced Fit Effects. J Med Chem 49: 534-553.
30. Sherman W, Beard HS, Farid R, (2006) Use of an Induced Fit Receptor Structure in Virtual Screening. Chem Biol Drug Des 67: 83-84.
31. Farid R, Day T, Friesner RA, Pearlstein RA, (2006) New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. Bioorg & Med Chem 14: 3160-3173.
32. Ng CY, Gu F, Phong WY, Chen YL, Lim SP, et al. (2007) Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Antiviral Res 76: 222-231.
33. Low JG, Ooi EE, Tolfvenstam T, Leo YS, Hibberd ML, et al. (2006) Early Dengue Infection and Outcome Study (EDEN) - Study Design and Preliminary Findings. Ann Acad Med Singapore 35: 783-789.
34. Nagasawa K, Harada H, Hayashi S, Misawa T, (1972) Sulfation of dextran with piperidine-N-sulfonic acid. Carbohydr Res 21: 420-426.
35. Yoshida T, Hatanaka K, Uryu T, Kaneko Y, Suzuki E, et al. (1990) Synthesis and structural analysis of curdlan sulfate with a potent inhibitory effect in vitro of AIDS virus infection. Macromolecules 23 (16) (): 3717-3722.
36. Parida MM, Pandya G, Bhargava R, Bhattacharya R, Jana AM, (1999) Comparison of two colorimetric assays to determine viral infectivity in micro culture virus titration. Indian J Exp Biol 37: 1223-1226.
37. Pannecouque C, Daelemans D, De Clercq E, (2008) Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat Protoc 3: 427-434.
38. Muschin T, Han S, Kanamoto T, Nakashima H, Yoshida T, (2011) Synthesis and specific influenza A virus-adsorptive functionality of alkyl curdlan sulfate-coated membrane filter. J Polym Sci A Polym Chem 49: 3241-3247.
39. Daelemans D, Pauwels R, De Clercq E, Pannecouque C, (2011) A time-of-drug addition approach to target identification of antiviral compounds. Nat Protoc 6: 925-933.
40. Randolph VB, Stollar V, (1990) Low pH-induced cell fusion in flavivirus-infected Aedes albopictus cell cultures. J Gen Virol 71: 1845-1850.
41. Rajamanonmani R, Nkenfou C, Clancy P, Yau YH, Shochat SG, et al. (2009) On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J Gen Virol 90: 799-809.
42. Rathore AP, Paradkar PN, Watanabe S, Tan KH, Sung C, et al. (2011) Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Antiviral Res 92: 453-460.
43. Chan KR, Zhang SL, Tan HC, Chan YK, Chow A, et al. (2011) Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci U S A 108: 12479-12484.
44. Lai YL, Chung YK, Tan HC, Yap HF, Yap G, et al. (2007) Cost-effective real-time reverse transcriptase PCR (RT-PCR) to screen for Dengue virus followed by rapid single-tube multiplex RT-PCR for serotyping of the virus. J Clin Microbiol 45: 935-941.
45. Alen MM, Kaptein SJ, De Burghgraeve T, Balzarini J, Neyts J, et al. (2009) Antiviral activity of carbohydrate-binding agents and the role of DC-SIGN in dengue virus infection. Virology 387: 67-75.
46. Talarico LB, Pujol CA, Zibetti RG, Faría PC, Noseda MD, et al. (2005) The antiviral activity of sulfated polysaccharides against dengue virus is dependent on virus serotype and host cell. Antiviral Res 66: 103-110.
47. Yin Z, Chen YL, Schul W, Wang QY, Gu F, et al. (2009) An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A 106: 20435-20439.
48. Mazumder R, Zhang-Zhi H, Vinayaka CR, Sagripanti J, Frost SDW, et al. (2007) Computational analysis and identification of amino acid sites in dengue E proteins relevant to development of diagnostics and vaccines. Virus Genes 35: 175-186.
49. Laskowski RA, Swindells MB, (2011) LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 51: 2778-2786.
50. Pujol CA, Ray S, Ray B, Damonte EB, (2012) Antiviral activity against dengue virus of diverse classes of algal sulfated polysaccharides. Int J Biol Macromol 51: 412-416.
51. Wang E, Ni H, Xu R, Barrett AD, Watowich SJ, et al. (2000) Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J Virol 74: 3227-3234.
52. Acosta EG, Castilla V, Damonte EB, (2009) Alternative infectious entry pathways for dengue virus serotypes into mammalian cells. Cellular Microbiology 11: 1533-1549.
53. Rothman AL, (2011) Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 11: 532-543.
54. Gordon M, Deeks S, De Marzo C, Goodgame J, Guralnik M, et al. (1997) Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity. J Med 28: 108-28.
55. Baba M, Snoeck R, Pauwels R, de Clercq E, (1988) Sulfated polysaccharides are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, and human immunodeficiency virus. Antimicrob Agents Chemother 32: 1742-1745.
56. Jagodzinski PP, Wiaderkiewicz R, Kurzawski G, Kloczewiak M, Nakashima H, et al. (1994) Mechanism of the inhibitory effect of curdlan sulfate on HIV-1 infection in vitro. Virology 202: 735-745.
57. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, et al. (1997) Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nature Medicine 3: 866-871.
58. Abd Jamil J, Cheah CY, AbuBakar S, (2008) Dengue virus type 2 envelope protein displayed as recombinant phage attachment protein reveals potential cell binding sites. Protein Eng Des Sel 21: 605-611.
59. Costin JM, Jenwitheesuk E, Lok S-M, Hunsperger E, Conrads KA, et al. (2010) Structural Optimization and De Novo Design of Dengue Virus Entry Inhibitory Peptides. PLoS Negl Trop Dis 4: e721.
60. Halstead SB, (1970) Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion. Yale J Biol Med 42: 350-362.
61. Geijtenbeek TB, Krooshoop DJ, Bleijs DA, van Vliet SJ, van Duijnhoven GC, et al. (2000) DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking. Nat Immunol 1: 353-357.
62. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, et al. (2003) DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 197: 823-829.
63. Sanders RW, de Jong EC, Baldwin CE, Schuitemaker JH, Kapsenberg ML, et al. (2002) Differential transmission of human immunodeficiency virus type 1 by distinct subsets of effector dendritic cells. J Virol 76: 7812-7821.
64. Koppel EA, van Gisbergen KP, Geijtenbeek TB, van Kooyk Y, (2005) Distinct functions of DC-SIGN and its homologues L-SIGN (DC-SIGNR) and mSIGNR1 in pathogen recognition and immune regulation. Cell Microbiol 7: 157-165.
65. Havlik I, Rovelli S, Kaneko Y, (1994) The effect of curdlan sulphate on in vitro growth of Plasmodium falciparum. Trans R Soc Trop Med Hyg 88: 686-687.
66. Igarashi I, Njonge FK, Kaneko Y, Nakamura Y, (1998) Babesia bigemina: in vitro and in vivo effects of curdlan sulfate on growth of parasites. Exp Parasitol 90: 290-293.
67. Gordon M, Deeks S, De Marzo C, Goodgame J, Guralnik M, et al. (1997) Curdlan sulfate (CRDS) in a 21-day intravenous tolerance study in human immunodeficiency virus (HIV) and cytomegalovirus (CMV) infected patients: indication of anti-CMV activity with low toxicity. J Med 28: 108-128.
68. Gordon M, Guralnik M, Kaneko Y, Mimura T, Baker M, et al. (1994) A phase I study of curdlan sulfate-an HIV inhibitor. Tolerance, pharmacokinetics and effects on coagulation and on CD4 lymphocytes. J Med 25: 163-180.